📄 Extracted Text (231 words)
From: Paul Morris
Sent: 5/14/2015 12:07:08 PM
To: jeffrey E. [[email protected]
Subject: quick discussion about pharma financing opportunity? [C]
Classification: Confidential
jeffrey, we are working on a live situation with a pharma company that is looking to finance the distribution and sales of
a newly approved drug. DB is bidding on the debt financing and would need to syndicate out —$50mm to a third party. I
expect the transaction to be structured as a royalty arrangement and imagine yields would be in the low double digits. I
know you've done equity transactions in biotech area over the years but thought you may have someone interested in a
discussion with our structured credit team to see if this would be a fit? Let's catch up soon.
Hope all is well,
Paul Morris
Managing Director
Deutsche Bank Private Bank
Office:
Cell:
asun. #1r peefoyst,
Securities offered through Deutsche Bank Securities Inc.
This communication may contain confidential and/or privileged information. If you are not the intended
recipient (or have received this communication in error) please notify the sender immediately and
destroy this communication. Any unauthorized copying, disclosure or distribution of the material in
this communication is strictly forbidden.
Deutsche Bank does not render legal or tax advice, and the information contained in this
communication should not be regarded as such.
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0 102480
CONFIDENTIAL SDNY_GM_00248664
EFTA01447749
ℹ️ Document Details
SHA-256
01d5385e45c0e47dd8c7619976e83cae66dad612ef81407b691cca6f1649769f
Bates Number
EFTA01447749
Dataset
DataSet-10
Document Type
document
Pages
1
Comments 0